Biopharmaceutical firm Ardelyx's Q2 revenue rises 33%
Overview
Ardelyx Q2 2025 revenue grows 33% yr/yr to $97.7 mln
Co raises 2025 IBSRELA sales forecast to $250-$260 mln
Ardelyx ends Q2 with $238.5 mln in cash and investments
Outlook
Company raises 2025 IBSRELA net sales revenue expectations to $250-$260 mln
Ardelyx confident in XPHOZAH growth for remainder of 2025
Result Drivers
IBSRELA SALES GROWTH - IBSRELA net sales increased 84% yr/yr and 46% qtr/qtr, driven by strategic commercial execution and high demand
XPHOZAH DEMAND - XPHOZAH net sales revenue increased 27% qtr/qtr, driven by growing demand among healthcare providers
REVENUE INCREASE - Total revenue grew 33% yr/yr, attributed to increased IBSRELA and XPHOZAH sales
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Product Sales |
| $90.08 mln |
|
Q2 EPS |
| -$0.08 |
|
Q2 Net Income |
| -$19.08 mln |
|
Q2 Operating Expenses |
| $99.65 mln |
|
Q2 Operating Income |
| -$14.40 mln |
|
Press Release: ID:nGNX3rjB7b
